Natural haemozoin induces expression and release of human monocyte tissue inhibitor of metalloproteinase-1

PLoS One. 2013 Aug 14;8(8):e71468. doi: 10.1371/journal.pone.0071468. eCollection 2013.

Abstract

Recently matrix metalloproteinase-9 (MMP-9) and its endogenous inhibitor (tissue inhibitor of metalloproteinase-1, TIMP-1) have been implicated in complicated malaria. In vivo, mice with cerebral malaria (CM) display high levels of both MMP-9 and TIMP-1, and in human patients TIMP-1 serum levels directly correlate with disease severity. In vitro, natural haemozoin (nHZ, malarial pigment) enhances monocyte MMP-9 expression and release. The present study analyses the effects of nHZ on TIMP-1 regulation in human adherent monocytes. nHZ induced TIMP-1 mRNA expression and protein release, and promoted TNF-α, IL-1β, and MIP-1α/CCL3 production. Blocking antibodies or recombinant cytokines abrogated or mimicked nHZ effects on TIMP-1, respectively. p38 MAPK and NF-κB inhibitors blocked all nHZ effects on TIMP-1 and pro-inflammatory molecules. Still, total gelatinolytic activity was enhanced by nHZ despite TIMP-1 induction. Collectively, these data indicate that nHZ induces inflammation-mediated expression and release of human monocyte TIMP-1 through p38 MAPK- and NF-κB-dependent mechanisms. However, TIMP-1 induction is not sufficient to counterbalance nHZ-dependent MMP-9 enhancement. Future investigation on proteinase-independent functions of TIMP-1 (i.e. cell survival promotion and growth/differentiation inhibition) is needed to clarify the role of TIMP-1 in malaria pathogenesis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Cell Adhesion
  • Gene Expression Regulation / drug effects*
  • Hemeproteins / pharmacology*
  • Humans
  • MAP Kinase Signaling System / drug effects
  • Matrix Metalloproteinase 9 / metabolism
  • Mice
  • Monocytes / cytology
  • Monocytes / drug effects*
  • Monocytes / metabolism*
  • NF-kappa B / metabolism
  • RNA, Messenger / genetics
  • RNA, Messenger / metabolism
  • Solubility
  • Tissue Inhibitor of Metalloproteinase-1 / genetics*
  • Tissue Inhibitor of Metalloproteinase-1 / metabolism*
  • p38 Mitogen-Activated Protein Kinases / metabolism

Substances

  • Hemeproteins
  • NF-kappa B
  • RNA, Messenger
  • Tissue Inhibitor of Metalloproteinase-1
  • hemozoin
  • p38 Mitogen-Activated Protein Kinases
  • Matrix Metalloproteinase 9

Grants and funding

This work was financed by intramural funds from Università di Torino to G. Giribaldi, by funds from Mrs. Franca Squazza and from Società Italiana di Biochimica (SIB) to M. Prato, and by Fund for Scientific Research (FWO-Vlaanderen) and Research Fund of the KULeuven (GOA/2012/017) to G. Opdenakker and P. Van den Steen. M. Prato holds a professorship granted by Università di Torino and Azienda Sanitaria Locale-19 (ASL-19). P. Van den Steen holds a research professorship of the KULeuven. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.